azacitidine has been researched along with vorinostat in 89 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 15 (16.85) | 29.6817 |
| 2010's | 70 (78.65) | 24.3611 |
| 2020's | 4 (4.49) | 2.80 |
| Authors | Studies |
|---|---|
| Lombardo, F; Obach, RS; Waters, NJ | 1 |
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Davis, MI; Khan, J; Li, SQ; Patel, PR; Shen, M; Sun, H; Thomas, CJ | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Chiba, DE; Dos Santos, JL; Lopes, JR | 1 |
| Erdlenbruch, B; Kanbach, K; Monkemeyer, S; Pekrun, A; Reinhardt, D; Rönndahl, G; Witt, O | 1 |
| Ahsan, MK; Kim, YC; Maeda, M; Masutani, H; Matsuoka, M; Nishinaka, Y; Nosaka, K; Yamaguchi, Y; Yodoi, J | 1 |
| Mack, GS | 1 |
| Desmond, JC; Haferlach, T; Hofmann, WK; Koeffler, HP; Raynaud, S; Tung, E | 1 |
| Armeanu, S; Bitzer, M; Gregor, M; Hsieh, CJ; Lauer, UM; Pathil, A; Venturelli, S; Vonthein, R; Wehrmann, M; Weiss, TS | 1 |
| Chumakov, A; Gery, S; Imai, Y; Kawamata, N; Koeffler, HP; Komatsu, N; Kumagai, T; Takai, N; Wakimoto, N; Yin, D | 1 |
| Guichard, SM; Jodrell, DI; Patel, K | 1 |
| Hsu, HS; Hsu, WH; Lin, RK; Tseng, C; Tseng, RC; Wang, YC; Wen, CK | 1 |
| Beltran, AS; Blancafort, P; Lizardi, PM; Sun, X | 1 |
| Atadja, P; Bhalla, K; Chen, J; Eaton, K; Fernandez, P; Fiskus, W; Herger, B; Joshi, R; Kolhe, R; Lee, P; Mandawat, A; Peiper, S; Rao, R; Wang, Y; Yang, Y | 1 |
| Furukawa, Y | 1 |
| Billam, M; Davidson, NE; Sobolewski, MD | 1 |
| Cichewicz, RH; Fisch, KM; Gillaspy, AF; Gipson, M; Henrikson, JC; Hoover, AR; Jackson, L; Najar, FZ; Wägele, H | 1 |
| Scott, BL | 1 |
| Al-Sarraf, N; Baird, AM; Cathcart, MC; Gray, SG; McGovern, E; O'Byrne, KJ | 1 |
| Fujimoto, J; Hong, WK; Kong, M; Lee, JJ; Lotan, R | 1 |
| Hoffman, R; Li, Y; Lu, M; Najfeld, V; Tripodi, J; Wang, X; Xu, M; Zhang, W | 1 |
| Brodská, B; Holoubek, A; Otevřelová, P | 2 |
| Chen, EX; Egorin, MJ; Espinoza-Delgado, I; Hirte, HW; Holleran, JL; Hotte, SJ; Laughlin, A; McGill, S; Moretto, P; Oza, AM; Siu, LL; Stathis, A; Stayner, LA; Wang, L; Webster, S; Zhang, WJ | 1 |
| Ahmed, AA; Bast, RC; Bornmann, WG; Chen, MY; Hennessey, V; Liao, WS; Lu, Z; Rosner, GL; Washington, MN; Yu, Y | 1 |
| Blanquart, C; Boutin, B; Fonteneau, JF; Grégoire, M; Gueugnon, F; Guillot, F; Leclercq, S; Padieu, M; Pouliquen, D; Rogel, A | 1 |
| Maki, K; Mitani, K | 1 |
| Aw, D; Goh, BC; Hsieh, WS; Lee, SC; Pang, A; Tan, KB | 1 |
| Nalls, D; Rodova, M; Shankar, S; Srivastava, RK; Tang, SN | 1 |
| Brodská, B; Holoubek, A | 1 |
| de Lima, M; Koreth, J; Reddy, P | 1 |
| Terry, SY; Vallis, KA | 1 |
| Bardhan, K; Liu, K; McGaha, TL; Torres, CM; Yang, D; Zimmerman, M | 1 |
| Bhatla, T; Brown, P; Burke, MJ; Carroll, WL; Morrison, DJ; Raetz, EA; Wang, J | 1 |
| Abe, I; Awakawa, T; Noguchi, H; Sun, J | 1 |
| Goodson, H; Helquist, P; Huegel, KL; Hulett, TW; Vaughan, KT; Wehrmann, ZT; Wiest, O | 1 |
| Andry, G; De Martelar, V; Dom, G; Dumont, JE; Galdo, VC; Hébrant, A; Leteurtre, E; Libert, F; Maenhaut, C; Tarabichi, M; Tomás, G; van Staveren, WC | 1 |
| Cheriyath, V; Dermawan, JK; Labhasetwar, V; Vijayaraghavalu, S | 1 |
| Baylin, SB; Dai, C; Jones, PA; Liang, G; Pandiyan, K; Yang, X; You, JS; Zhou, XJ | 1 |
| Akkamsetty, Y; Callen, DF; Ho, K; Kumar, R; Lim, SP; Neilsen, PM; Prestidge, C; Suetani, RJ; Walther, DJ; Wang, W | 1 |
| Wolfson, W | 1 |
| Held, G; Kaddu-Mulindwa, D; Kubuschok, B; Neumann, F; Pfreundschuh, M; Preuss, KD; Roemer, K; Widmann, T; Zwick, C | 1 |
| Boumber, Y; Fang, Z; Garcia-Manero, G; Gonzalez-Cervantes, EA; Kuang, SQ; Wei, Y; Yang, H; Zweidler-McKay, PA | 1 |
| Ellinger, J; Müller, SC; Schiffgen, M; Schmidt, DH; von Rücker, A | 1 |
| Adès, L; Ame, S; Beyne-Rauzy, O; Braun, T; Charbonnier, A; Delaunay, J; Dreyfus, F; Fenaux, P; Prebet, T; Raffoux, E; Stammatoullas, A; Vey, N; Wattel, E | 1 |
| Brodská, B; Holoubek, A; Kuželová, K; Otevřelová, P | 1 |
| Estey, EH; Gallegos, L; Gardner, KM; Hendrie, PC; Medeiros, BC; Orlowski, KF; Scott, BL; Walter, RB | 1 |
| Ashktorab, H; Brim, H; Brodeur, GM; Fatemi, M; Paul, TA; Shokrani, B | 1 |
| Ewing, R; Scott, A; Song, J; Wang, Z | 1 |
| Camilloni, G; Capitano, F; Deiana, C; Fragapane, P; Gaglio, D; Mastrodonato, A; Mele, A; Minicocci, E | 1 |
| Burke, MJ; Cao, X; Ghodke-Puranik, Y; Lamba, JK; Lindgren, BR; Miller, JS; Pounds, S; Verneris, MR; Weigel, BJ | 1 |
| Fanger, G; Knox, S; Oronsky, B; Oronsky, N; Scicinski, J | 1 |
| Bredeson, C; Eid, JE; Frankel, P; Gojo, I; Goldberg, SL; Issa, JP; Kirschbaum, M; Kujawski, LA; Lubiniecki, GM; Marks, P; Sun, X; Tosolini, A; Yang, A | 1 |
| Kouraklis, G; Nebiker, CA; Tampaki, EC; Tampakis, A | 1 |
| Borchardt, C; Clemens, D; Dirksen, U; Frühwald, MC; Kool, M; Unland, R | 1 |
| Fujinaga, K; Luo, Z; Peterlin, BM; Schaufele, F | 1 |
| Mukherjee, S; Ornstein, MC; Sekeres, MA | 1 |
| Brandwein, J; Brian, L; Chen, EX; Degelder, T; Egorin, MJ; Espinoza-Delgado, I; Gupta, V; Haines, P; Holleran, JL; How, J; McGill, S; Minden, MD; Piekarz, R; Schimmer, AD; Schuh, AC; Siu, LL; Stayner, LA; Wang, L; Webster, S; Wong, T; Yee, KW | 1 |
| Damm, OS; Ehmcke, J; Gromoll, J; Kläver, R; Lahrmann, E; Redmann, K; Rohde, C; Sánchez, V; Sandhowe-Klaverkamp, R; Schlatt, S; Wistuba, J | 1 |
| Biankin, AV; Caldon, CE; Chang, DK; Colvin, EK; Henshall, SM; Mawson, A; Musgrove, EA; Pajic, M; Pinese, M; Scarlett, CJ; Susanto, JM; Sutherland, RL | 1 |
| Bian, YM; Liu, JH; Lu, DP; Xie, Y | 1 |
| Ahrens, TD; Boerries, M; Busch, H; Follo, M; Hembach, S; Hoeppner, J; Hopt, UT; Lassmann, S; Ostendorp, J; Timme, S; Werner, M | 1 |
| Jelicks, L; Liang, Y; Liu, J; Ma, S; Mei, J; Perez-Soler, R; Zeng, J; Zou, Y | 1 |
| Beckhove, P; Gal, Z; Grabe, N; Herold-Mende, C; Lahrmann, B; Lasitschka, F; Mock, A; Mossemann, J; Schmezer, P; Schmoch, T; Unterberg, A | 1 |
| Ahmed, S; Alousi, A; Anderlini, P; Andersson, BS; Bashir, Q; Champlin, R; Dabaja, B; Fanale, M; Gulbis, A; Hosing, C; Jones, RB; Myers, A; Nieto, Y; Oki, Y; Pinnix, C; Popat, U; Qazilbash, M; Shah, N; Shpall, EJ; Thall, PF; Valdez, BC; Wei, W | 1 |
| Glasow, A; Kortmann, RD; Menzel, F; Patties, I | 1 |
| Doroshow, JH; Hose, C; Krushkal, J; Monks, A; Simon, R; Zhao, Y | 1 |
| Ahn, H; Cerchietti, L; Elstrom, R; Furman, R; Leonard, J; Martin, P; Marullo, R; Patel, J; Pera, B; Ruan, J; Tang, T; Yang, SN | 1 |
| Clemens, D; Dirksen, U; Hotfilder, M; Klco-Brosius, S; Pettke, A; Potratz, J; Schaefer, C | 1 |
| Condom, E; Esteller, M; Gomez, A; Moran, S; Romero, OA; Sanchez-Cespedes, M; Torres-Diz, M; Verdura, S; Villanueva, A | 1 |
| Clozel, T; Elemento, O; Erdem, Z; Hassler, MR; Krzywinski, M; Robinson, BD; Shariat, SF; Xylinas, E; Zhuang, D | 1 |
| Ali, A; Chaubey, A; Jain, SK; Nalli, Y; Qadri, M; Riyaz-Ul-Hassan, S; Strobel, GA; Vishwakarma, RA | 1 |
| Braun, T; Chermat, F; Chevret, S; Cony-Makhoul, P; Delaunay, J; Dimicoli, S; Fenaux, P; Lejeune, J; Prebet, T; Vey, N; Wattel, E; Wickenhauser, S | 1 |
| Blednov, YA; Harris, RA; Mayfield, RD; Morikawa, H; Ponomarev, I; Stelly, CE | 1 |
| Appelbaum, FR; Atallah, E; Attar, EC; Bloomfield, CD; Buckstein, R; Cook, EK; Cull, AH; Erba, HP; Fang, M; Gaur, R; Gore, SD; List, AF; Litzow, MR; Moseley, A; Nazha, A; Odenike, O; Othus, M; Rauh, MJ; Roulston, D; Sekeres, MA; Stone, RM; Velasco, MR; Zhang, Y | 1 |
| Craddock, C | 1 |
| Eslin, D; Glade Bender, JL; Glasser, CL; Lee, A; Marks, L; Modak, S | 1 |
| Abdollahi, M; Rahmani, S | 1 |
| Alqinyah, M; Hooks, SB | 1 |
| Ahmad, B; Ali, J; Bacha, N; Bakht, J; Khan, AA; Lutfullah, G | 1 |
| Han, T; Hu, H; Jiao, F; Wang, LW; Zhuo, M | 1 |
| Brand, OJ; Jenkins, G; Knox, AJ; Pang, L; Pasini, A | 1 |
| Booth, S; Cheng, P; Craddock, C; De Santo, C; Fultang, L; Kearns, P; Keeshan, K; Mussai, F; Perry, T; Sarrou, E; Stavrou, V; Wheat, R | 1 |
| Dwibedi, V; Kalia, S; Saxena, S | 1 |
| Kubasch, AS; Platzbecker, U | 1 |
| Aldholmi, M; Ganesan, A; Wilkinson, B | 1 |
| Chhabra, R; Guergues, J; Hill, R; Nadeau, OW; Nanjundan, M; Rockfield, S; Stevens, SM | 1 |
| Cooper, PR; Duncan, HF; Kearney, M; Smith, AJ | 1 |
11 review(s) available for azacitidine and vorinostat
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
HIV latency reversal agents: A potential path for functional cure?
Topics: Anti-HIV Agents; CD4-Positive T-Lymphocytes; Histone Deacetylase Inhibitors; HIV Infections; HIV-1; Humans; Molecular Structure; Virus Latency | 2021 |
[Epigenetics in hematological disorders].
Topics: Antineoplastic Agents; Azacitidine; Depsipeptides; DNA Methylation; Drug Design; Enzyme Inhibitors; Epigenesis, Genetic; Gene Expression Regulation, Neoplastic; Hematologic Neoplasms; Histone Deacetylase Inhibitors; Histone Deacetylases; Histones; Humans; Hydroxamic Acids; Mutation; Nucleosomes; Transcription, Genetic; Vorinostat | 2008 |
[Epigenetic therapy in myelodysplastic syndromes].
Topics: Azacitidine; Decitabine; Depsipeptides; DNA Methylation; DNA Modification Methylases; Drug Design; Drug Therapy, Combination; Epigenesis, Genetic; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Molecular Targeted Therapy; Myelodysplastic Syndromes; Randomized Controlled Trials as Topic; Vorinostat | 2011 |
Emerging therapies in hematopoietic stem cell transplantation.
Topics: Antineoplastic Agents; Azacitidine; Boronic Acids; Bortezomib; Graft vs Host Disease; Graft vs Tumor Effect; Hematopoietic Stem Cell Transplantation; Humans; Hydroxamic Acids; Proteasome Inhibitors; Pyrazines; Vorinostat | 2012 |
Regulation of protein stability of DNA methyltransferase 1 by post-translational modifications.
Topics: Antineoplastic Combined Chemotherapy Protocols; Azacitidine; DNA (Cytosine-5-)-Methyltransferase 1; DNA (Cytosine-5-)-Methyltransferases; DNA Methylation; Humans; Hydroxamic Acids; Neoplasms; Protein Processing, Post-Translational; Protein Stability; Vorinostat | 2014 |
Episensitization: therapeutic tumor resensitization by epigenetic agents: a review and reassessment.
Topics: Animals; Antineoplastic Agents; Azacitidine; Azetidines; Benzamides; Decitabine; DNA Modification Methylases; Drug Resistance, Neoplasm; Epigenesis, Genetic; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Neoplasms; Nitro Compounds; Oxidative Stress; Pyridines; Vorinostat | 2014 |
Histone deacetylase inhibitors and colorectal cancer: what is new?
Topics: Antineoplastic Agents; Azacitidine; Colorectal Neoplasms; Combined Modality Therapy; Decitabine; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Valproic Acid; Vorinostat | 2014 |
More is better: combination therapies for myelodysplastic syndromes.
Topics: Antineoplastic Agents; Azacitidine; Benzamides; Clinical Trials as Topic; Decitabine; Disease Progression; Drug Therapy, Combination; Gene Expression; Histone Deacetylase Inhibitors; Histone Deacetylases; Humans; Hydroxamic Acids; Lenalidomide; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes; Pyrimidines; Thalidomide; Valproic Acid; Vorinostat | 2015 |
Novel treatment opportunities for sulfur mustard-related cancers: genetic and epigenetic perspectives.
Topics: Antimetabolites, Antineoplastic; Azacitidine; Cancer Vaccines; Carcinogens; Chemical Warfare Agents; Decitabine; Epigenesis, Genetic; Genetic Therapy; Humans; Hydroxamic Acids; Mustard Gas; Neoplasms; Oncolytic Virotherapy; Vorinostat | 2017 |
Regulating the regulators: Epigenetic, transcriptional, and post-translational regulation of RGS proteins.
Topics: Animals; Azacitidine; Benzodiazepines; Cardiovascular Diseases; Drugs, Investigational; Epigenesis, Genetic; GTP-Binding Proteins; Humans; Hydroxamic Acids; Neoplasms; Neurodegenerative Diseases; Olanzapine; Protein Processing, Post-Translational; RGS Proteins; Signal Transduction; Vorinostat | 2018 |
11 trial(s) available for azacitidine and vorinostat
| Article | Year |
|---|---|
Phase I study of decitabine in combination with vorinostat in patients with advanced solid tumors and non-Hodgkin's lymphomas.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; CpG Islands; Decitabine; Disease Progression; DNA Methylation; Epigenesis, Genetic; Female; Humans; Hydroxamic Acids; Lymphoma, Non-Hodgkin; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Promoter Regions, Genetic; Time Factors; Vorinostat | 2011 |
Epigenetic reprogramming reverses the relapse-specific gene expression signature and restores chemosensitivity in childhood B-lymphoblastic leukemia.
Topics: Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Blast Crisis; Cell Line, Tumor; Child; Child, Preschool; Cohort Studies; Decitabine; DNA Methylation; Female; Gene Expression Regulation, Leukemic; Gene Silencing; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Leukemia, B-Cell; Male; Vorinostat | 2012 |
Combination of vorinostat and low dose cytarabine for patients with azacitidine-refractory/relapsed high risk myelodysplastic syndromes.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Cytarabine; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Humans; Hydroxamic Acids; In Vitro Techniques; Middle Aged; Myelodysplastic Syndromes; Nausea; Neutropenia; Recurrence; Risk Factors; Survival Analysis; Thrombocytopenia; Treatment Outcome; Vomiting; Vorinostat | 2014 |
Gemtuzumab ozogamicin in combination with vorinostat and azacitidine in older patients with relapsed or refractory acute myeloid leukemia: a phase I/II study.
Topics: Age Factors; Aged; Aminoglycosides; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Female; Gemtuzumab; Humans; Hydroxamic Acids; Leukemia, Myeloid, Acute; Male; Middle Aged; Recurrence; Remission Induction; Treatment Outcome; Vorinostat | 2014 |
A therapeutic trial of decitabine and vorinostat in combination with chemotherapy for relapsed/refractory acute lymphoblastic leukemia.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Child; Child, Preschool; Decitabine; Disease-Free Survival; DNA Methylation; Drug Resistance, Neoplasm; Humans; Hydroxamic Acids; Middle Aged; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Secondary Prevention; Vorinostat; Young Adult | 2014 |
A phase 1 clinical trial of vorinostat in combination with decitabine in patients with acute myeloid leukaemia or myelodysplastic syndrome.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Decitabine; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Hydroxamic Acids; Leukemia, Myeloid, Acute; Male; Maximum Tolerated Dose; Middle Aged; Myelodysplastic Syndromes; Treatment Outcome; Vorinostat; Young Adult | 2014 |
A phase I trial of two sequence-specific schedules of decitabine and vorinostat in patients with acute myeloid leukemia.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Decitabine; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Leukemia, Myeloid, Acute; Male; Maximum Tolerated Dose; Middle Aged; Recurrence; Remission Induction; Retreatment; Treatment Outcome; Vorinostat | 2015 |
Combinatorial epigenetic therapy in diffuse large B cell lymphoma pre-clinical models and patients.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Cell Line, Tumor; Decitabine; DNA Methylation; Epigenesis, Genetic; Female; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Lymphoma, Large B-Cell, Diffuse; Male; Middle Aged; Treatment Outcome; Vorinostat | 2016 |
Addition of suberoylanilide hydroxamic acid (Vorinostat) to azacitidine for patients with higher risk myelodysplastic syndromes and azacitidine failure: a phase II add-on study from the Groupe Francophone des Myelodysplasies.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Disease-Free Survival; Humans; Kaplan-Meier Estimate; Myelodysplastic Syndromes; Risk Factors; Treatment Outcome; Vorinostat | 2018 |
Randomized Phase II Study of Azacitidine Alone or in Combination With Lenalidomide or With Vorinostat in Higher-Risk Myelodysplastic Syndromes and Chronic Myelomonocytic Leukemia: North American Intergroup Study SWOG S1117.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Humans; Hydroxamic Acids; Lenalidomide; Leukemia, Myelomonocytic, Chronic; Middle Aged; Myelodysplastic Syndromes; Thalidomide; Vorinostat | 2017 |
Targeting the arginine metabolic brake enhances immunotherapy for leukaemia.
Topics: Acute Disease; Antigens, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; Arginase; Arginine; Azacitidine; Humans; Immunotherapy; K562 Cells; Leukemia, Myeloid; Receptors, Chimeric Antigen; Sialic Acid Binding Ig-like Lectin 3; T-Lymphocytes; Tumor Microenvironment; Vorinostat | 2019 |
67 other study(ies) available for azacitidine and vorinostat
| Article | Year |
|---|---|
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Identification of potent Yes1 kinase inhibitors using a library screening approach.
Topics: Binding Sites; Cell Line; Cell Survival; Drug Design; Humans; Hydrogen Bonding; Molecular Docking Simulation; Protein Kinase Inhibitors; Protein Structure, Tertiary; Proto-Oncogene Proteins c-yes; Small Molecule Libraries; Structure-Activity Relationship | 2013 |
Induction of fetal hemoglobin expression by the histone deacetylase inhibitor apicidin.
Topics: Amides; Azacitidine; Benzamides; Butyrates; Enzyme Inhibitors; Fetal Hemoglobin; Gene Expression Regulation; Gene Expression Regulation, Leukemic; Globins; Histone Deacetylase Inhibitors; Histone Deacetylases; Histones; Humans; Hydroxamic Acids; Hydroxyurea; Imidazoles; K562 Cells; MAP Kinase Signaling System; Mitogen-Activated Protein Kinases; Neoplasm Proteins; p38 Mitogen-Activated Protein Kinases; Peptides, Cyclic; Phenylbutyrates; Pyridines; Vorinostat | 2003 |
Loss of interleukin-2-dependency in HTLV-I-infected T cells on gene silencing of thioredoxin-binding protein-2.
Topics: Acetylation; Azacitidine; Carrier Proteins; Cell Line, Tumor; Cell Transformation, Viral; Chromatin Immunoprecipitation; CpG Islands; Decitabine; DNA Methylation; DNA Modification Methylases; Enzyme Inhibitors; Gene Expression Regulation, Viral; Gene Silencing; Histone Deacetylase Inhibitors; Histones; Human T-lymphotropic virus 1; Humans; Hydroxamic Acids; Interleukin-2; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Signal Transduction; T-Lymphocytes; Thioredoxins; Transcription, Genetic; Vorinostat | 2006 |
Epigenetic cancer therapy makes headway.
Topics: Acetylation; Animals; Antineoplastic Agents; Azacitidine; Decitabine; DNA Methylation; Epigenesis, Genetic; Gene Expression Regulation, Neoplastic; Histone Deacetylases; Humans; Hydroxamic Acids; Methyltransferases; Neoplasms; Randomized Controlled Trials as Topic; Valproic Acid; Vorinostat | 2006 |
Discovery of epigenetically silenced genes in acute myeloid leukemias.
Topics: alpha Catenin; Azacitidine; Carrier Proteins; CpG Islands; Decitabine; DNA Methylation; Epigenesis, Genetic; Genes, Tumor Suppressor; Humans; Hydroxamic Acids; Leukemia, Myeloid, Acute; Reverse Transcriptase Polymerase Chain Reaction; Vorinostat | 2007 |
Epigenetic combination therapy as a tumor-selective treatment approach for hepatocellular carcinoma.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Proliferation; Decitabine; DNA Methylation; DNA Modification Methylases; Drug Screening Assays, Antitumor; Epigenesis, Genetic; Female; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Liver Neoplasms; Mice; Mice, Inbred BALB C; Neoplasm Transplantation; Vorinostat | 2007 |
Histone deacetylase inhibitor, suberoylanilide hydroxamic acid (Vorinostat, SAHA) profoundly inhibits the growth of human pancreatic cancer cells.
Topics: Annexin A5; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Azacitidine; Cell Cycle; Cell Differentiation; Cell Line, Tumor; Cell Proliferation; Decitabine; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; Enzyme Inhibitors; Humans; Hydroxamic Acids; Methylation; Pancreatic Neoplasms; Vorinostat | 2007 |
Simultaneous determination of decitabine and vorinostat (Suberoylanalide hydroxamic acid, SAHA) by liquid chromatography tandem mass spectrometry for clinical studies.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Chromatography, High Pressure Liquid; Decitabine; Freezing; Humans; Hydroxamic Acids; Reference Standards; Reproducibility of Results; Solutions; Tandem Mass Spectrometry; Vorinostat | 2008 |
Epigenetic silencing of AXIN2/betaTrCP and deregulation of p53-mediated control lead to wild-type beta-catenin nuclear accumulation in lung tumorigenesis.
Topics: Active Transport, Cell Nucleus; Axin Protein; Azacitidine; beta Catenin; beta-Transducin Repeat-Containing Proteins; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Nucleus; Cytoskeletal Proteins; Decitabine; DNA Methylation; Epigenesis, Genetic; Gene Silencing; Humans; Hydroxamic Acids; Lung Neoplasms; Prognosis; Promoter Regions, Genetic; Tumor Suppressor Protein p53; Vorinostat | 2008 |
Reprogramming epigenetic silencing: artificial transcription factors synergize with chromatin remodeling drugs to reactivate the tumor suppressor mammary serine protease inhibitor.
Topics: Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Chromatin Assembly and Disassembly; Decitabine; Gene Silencing; Genes, Tumor Suppressor; Humans; Hydroxamic Acids; Models, Biological; Serine Proteinase Inhibitors; Serpins; Transcription Factors; Tumor Cells, Cultured; Vorinostat | 2008 |
Molecular and biologic characterization and drug sensitivity of pan-histone deacetylase inhibitor-resistant acute myeloid leukemia cells.
Topics: Acetylation; Animals; Antineoplastic Agents; Apoptosis; Azacitidine; Benzoquinones; Cell Differentiation; Cell Proliferation; Decitabine; DNA-Binding Proteins; Drug Resistance, Neoplasm; Enzyme Inhibitors; Heat Shock Transcription Factors; Histone Deacetylase Inhibitors; HL-60 Cells; HSP70 Heat-Shock Proteins; HSP90 Heat-Shock Proteins; Humans; Hydroxamic Acids; Indoles; Lactams, Macrocyclic; Leukemia, Myeloid, Acute; Mice; Mice, Inbred NOD; Neoplasm Proteins; Panobinostat; S Phase; Transcription Factors; Tubulin; Vorinostat | 2008 |
Effects of a novel DNA methyltransferase inhibitor zebularine on human breast cancer cells.
Topics: Adenocarcinoma; Apoptosis Regulatory Proteins; Azacitidine; Breast Neoplasms; Cell Cycle Proteins; Cell Line, Tumor; Chromatin Immunoprecipitation; Cytidine; Cytidine Deaminase; Decitabine; DNA (Cytosine-5-)-Methyltransferases; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; Drug Synergism; Enzyme Inhibitors; Female; Gene Expression Regulation, Neoplastic; Humans; Hydroxamic Acids; Neoplasm Proteins; Receptors, Estrogen; S Phase; Tumor Stem Cell Assay; Vorinostat | 2010 |
Chemical induction of silent biosynthetic pathway transcription in Aspergillus niger.
Topics: Aspergillus niger; Azacitidine; Biological Products; Biosynthetic Pathways; Biotechnology; Epigenesis, Genetic; Expressed Sequence Tags; Fungal Proteins; Gene Expression Regulation, Fungal; Gene Library; Hydroxamic Acids; Multigene Family; Peptide Synthases; Polyketide Synthases; Reverse Transcriptase Polymerase Chain Reaction; Up-Regulation; Vorinostat | 2009 |
Clinical roundtable monograph. Combination therapies for MDS.
Topics: Azacitidine; Carrier Proteins; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Colony-Stimulating Factors; Enzyme Inhibitors; Etanercept; Humans; Hydroxamic Acids; Immunoglobulin G; Lenalidomide; Myelodysplastic Syndromes; Platelet Transfusion; Receptors, Fc; Receptors, Tumor Necrosis Factor; Recombinant Fusion Proteins; Thalidomide; Thrombopoietin; Valproic Acid; Vorinostat | 2009 |
Regulation of EP receptors in non-small cell lung cancer by epigenetic modifications.
Topics: Acetylation; Antineoplastic Agents; Azacitidine; Carcinoma, Non-Small-Cell Lung; Cell Proliferation; Chromatin Assembly and Disassembly; CpG Islands; Decitabine; DNA Methylation; Epigenesis, Genetic; Gene Expression Regulation, Neoplastic; Histone Deacetylase Inhibitors; Histones; Humans; Hydroxamic Acids; Lung Neoplasms; Phenylbutyrates; Receptors, Prostaglandin E; RNA, Messenger; Tumor Cells, Cultured; Vorinostat | 2009 |
Validation of a novel statistical model for assessing the synergy of combined-agent cancer chemoprevention.
Topics: Algorithms; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Cell Line, Tumor; Cell Proliferation; Cell Transformation, Neoplastic; Chemoprevention; Decitabine; Dose-Response Relationship, Drug; Drug Evaluation, Preclinical; Drug Synergism; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Models, Statistical; Neoplasms; Vorinostat | 2010 |
Sequential treatment of CD34+ cells from patients with primary myelofibrosis with chromatin-modifying agents eliminate JAK2V617F-positive NOD/SCID marrow repopulating cells.
Topics: Animals; Antigens, CD34; Antimetabolites, Antineoplastic; Antineoplastic Agents; Azacitidine; Bone Marrow; Cells, Cultured; Chromatin; Decitabine; Hematopoietic Stem Cells; Humans; Hydroxamic Acids; Immunoblotting; Interleukin Receptor Common gamma Subunit; Janus Kinase 2; Mice; Mice, Inbred NOD; Mice, Knockout; Mice, SCID; Mutation; Primary Myelofibrosis; Protein Synthesis Inhibitors; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Vorinostat | 2010 |
Decitabine-induced apoptosis is derived by Puma and Noxa induction in chronic myeloid leukemia cell line as well as in PBL and is potentiated by SAHA.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Apoptosis Regulatory Proteins; Azacitidine; Cells, Cultured; Decitabine; Drug Evaluation, Preclinical; Drug Synergism; Gene Expression Regulation, Leukemic; Humans; Hydroxamic Acids; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Lymphocytes; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-bcl-2; Up-Regulation; Vorinostat | 2011 |
Decitabine and suberoylanilide hydroxamic acid (SAHA) inhibit growth of ovarian cancer cell lines and xenografts while inducing expression of imprinted tumor suppressor genes, apoptosis, G2/M arrest, and autophagy.
Topics: Animals; Antimetabolites, Antineoplastic; Apoptosis; Autophagy; Azacitidine; Cell Division; Cell Line, Tumor; Cell Proliferation; Decitabine; Drug Synergism; Drug Therapy, Combination; Epigenomics; Female; G2 Phase; Gene Expression Regulation, Neoplastic; Genes, Tumor Suppressor; Genomic Imprinting; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Mice; Mice, Inbred BALB C; Mice, Nude; Ovarian Neoplasms; Transplantation, Heterologous; Vorinostat | 2011 |
A 5-aza-2'-deoxycytidine/valproate combination induces cytotoxic T-cell response against mesothelioma.
Topics: Animals; Antigens, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Cell Line, Tumor; Cell Proliferation; Decitabine; DNA Modification Methylases; Drug Synergism; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Membrane Proteins; Mesothelioma; Mice; Mice, Inbred C57BL; Neoplasm Transplantation; Pleural Neoplasms; T-Lymphocytes, Cytotoxic; Valproic Acid; Vorinostat | 2011 |
A case of Sweet's syndrome due to 5-Azacytidine and vorinostat in a patient with NK/T cell lymphoma.
Topics: Adult; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Female; Humans; Hydroxamic Acids; Lymphoma, Extranodal NK-T-Cell; Sweet Syndrome; Vorinostat | 2012 |
Targeting epigenetic regulation of miR-34a for treatment of pancreatic cancer by inhibition of pancreatic cancer stem cells.
Topics: Apoptosis; Azacitidine; Cell Cycle; Cell Line, Tumor; Cell Movement; Cell Proliferation; Chromatin; Epigenesis, Genetic; Epithelial-Mesenchymal Transition; Gene Expression Regulation, Neoplastic; Humans; Hydroxamic Acids; MicroRNAs; Neoplasm Invasiveness; Neoplastic Stem Cells; Pancreatic Neoplasms; Spheroids, Cellular; Tumor Stem Cell Assay; Up-Regulation; Vorinostat | 2011 |
Generation of reactive oxygen species during apoptosis induced by DNA-damaging agents and/or histone deacetylase inhibitors.
Topics: Antineoplastic Agents; Apoptosis; Azacitidine; Butyrates; Caspase 3; Cell Line, Tumor; Cytostatic Agents; Dactinomycin; Decitabine; DNA Damage; Drug Synergism; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Poly(ADP-ribose) Polymerases; Reactive Oxygen Species; Vorinostat | 2011 |
Relationship between chromatin structure and sensitivity to molecularly targeted auger electron radiation therapy.
Topics: Analysis of Variance; Azacitidine; Cell Line, Tumor; Chromatin; Decitabine; DNA Damage; Electrons; Epidermal Growth Factor; ErbB Receptors; Histone Deacetylase Inhibitors; Histones; Humans; Hydroxamic Acids; Pentetic Acid; Radiation Tolerance; Radiopharmaceuticals; Radiotherapy; Sodium Chloride; Vorinostat | 2012 |
Decitabine and vorinostat cooperate to sensitize colon carcinoma cells to Fas ligand-induced apoptosis in vitro and tumor suppression in vivo.
Topics: Adaptor Proteins, Signal Transducing; Adoptive Transfer; Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Apoptosis Regulatory Proteins; Azacitidine; bcl-X Protein; CD8-Positive T-Lymphocytes; Cell Line, Tumor; Colonic Neoplasms; Decitabine; Fas Ligand Protein; Gene Expression Regulation, Neoplastic; Humans; Hydroxamic Acids; Membrane Proteins; Mice; Mitochondrial Proteins; Neoplasm Metastasis; Neoplasms, Experimental; Proto-Oncogene Proteins; Tumor Escape; Vorinostat | 2012 |
Induced production of mycotoxins in an endophytic fungus from the medicinal plant Datura stramonium L.
Topics: Alternaria; Azacitidine; Culture Media; Datura stramonium; DNA Modification Methylases; Enzyme Inhibitors; Fungal Proteins; Histone Deacetylase Inhibitors; Hydroxamic Acids; Mycotoxins; Plants, Medicinal; Vorinostat | 2012 |
Quantitative comparison of the efficacy of various compounds in lowering intracellular cholesterol levels in Niemann-Pick type C fibroblasts.
Topics: Azacitidine; beta-Cyclodextrins; Cells, Cultured; Child; Child, Preschool; Chloroquine; Chlorpromazine; Cholesterol; Decitabine; Dose-Response Relationship, Drug; Drug Synergism; Female; Fibroblasts; Humans; Hydroxamic Acids; Indoles; Intracellular Space; Male; Microscopy, Fluorescence; Mutation; Niemann-Pick Disease, Type C; Panobinostat; Sirolimus; Vorinostat | 2012 |
5-aza-2'-deoxycytidine has minor effects on differentiation in human thyroid cancer cell lines, but modulates genes that are involved in adaptation in vitro.
Topics: Antimetabolites, Antineoplastic; Apoptosis; Azacitidine; Carcinoma; Cell Differentiation; Cell Line, Tumor; Cell Movement; Cell Survival; Decitabine; Gene Expression Regulation, Neoplastic; Humans; Hydroxamic Acids; Oligonucleotide Array Sequence Analysis; Thyroid Gland; Thyroid Neoplasms; Vorinostat | 2013 |
Highly synergistic effect of sequential treatment with epigenetic and anticancer drugs to overcome drug resistance in breast cancer cells is mediated via activation of p21 gene expression leading to G2/M cycle arrest.
Topics: Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Breast Neoplasms; Carcinogens; Cell Cycle Checkpoints; Cell Division; Cell Line, Tumor; Cyclin-Dependent Kinase Inhibitor p21; Decitabine; DNA (Cytosine-5-)-Methyltransferase 1; DNA (Cytosine-5-)-Methyltransferases; Doxorubicin; Drug Resistance, Neoplasm; Drug Synergism; Epigenesis, Genetic; Epigenomics; Female; G2 Phase; Genes, Tumor Suppressor; Humans; Hydroxamic Acids; Internationality; MCF-7 Cells; Vorinostat | 2013 |
Functional DNA demethylation is accompanied by chromatin accessibility.
Topics: Azacitidine; Cell Line, Tumor; Chromatin; Decitabine; DNA Methylation; Genes, Tumor Suppressor; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Promoter Regions, Genetic; Vorinostat | 2013 |
Development of a novel cell-based assay system EPISSAY for screening epigenetic drugs and liposome formulated decitabine.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Azacitidine; Breast; Carrier Proteins; Cells, Cultured; Cytomegalovirus; Decitabine; DNA Methylation; Drug Screening Assays, Antitumor; Epigenesis, Genetic; Gene Expression Regulation; Genes, Reporter; Genetic Vectors; Humans; Hydroxamic Acids; Luminescent Proteins; Nitroreductases; Plasmids; Promoter Regions, Genetic; Red Fluorescent Protein; Repressor Proteins; RNA, Messenger; Unilamellar Liposomes; Vorinostat | 2013 |
Epigenetic cancer therapies emerge out of the lab into the limelight.
Topics: Antineoplastic Agents; Azacitidine; Benzamides; Clinical Trials as Topic; Depsipeptides; Drug Resistance, Neoplasm; Epigenomics; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Neoplasms; Pyridines; Vorinostat | 2013 |
EBV-transformed lymphoblastoid cell lines as vaccines against cancer testis antigen-positive tumors.
Topics: Antigen-Presenting Cells; Antigens, Neoplasm; Azacitidine; B-Lymphocytes; Cancer Vaccines; CD4-Positive T-Lymphocytes; CD8-Positive T-Lymphocytes; Cell Line, Transformed; Cell Line, Tumor; DNA (Cytosine-5-)-Methyltransferase 1; DNA (Cytosine-5-)-Methyltransferases; Gene Expression Regulation, Neoplastic; Herpesvirus 4, Human; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Interferon-gamma; Melanoma; Neoplasms; RNA, Messenger; Telomerase; Telomere; Tumor Necrosis Factor-alpha; Valproic Acid; Vorinostat | 2013 |
Epigenetic inactivation of Notch-Hes pathway in human B-cell acute lymphoblastic leukemia.
Topics: Apoptosis; Azacitidine; B-Lymphocytes; Basic Helix-Loop-Helix Transcription Factors; Blood Cells; Bone Marrow; Calcium-Binding Proteins; Cell Line, Tumor; Cell Lineage; Cell Proliferation; Decitabine; DNA Methylation; Epigenesis, Genetic; Gene Expression Profiling; Gene Expression Regulation, Leukemic; Gene Silencing; Hematopoiesis; Histones; Humans; Hydroxamic Acids; Intercellular Signaling Peptides and Proteins; Jagged-1 Protein; Leukemia, B-Cell; Membrane Proteins; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Precursor T-Cell Lymphoblastic Leukemia-Lymphoma; Receptor, Notch3; Receptors, Notch; Repressor Proteins; Serrate-Jagged Proteins; Signal Transduction; T-Lymphocytes; Transcription, Genetic; Vorinostat | 2013 |
Epigenetic regulation of microRNA expression in renal cell carcinoma.
Topics: Azacitidine; Carcinoma, Renal Cell; Cell Line, Tumor; Cell Proliferation; Cell Survival; Decitabine; DNA Methylation; DNA Modification Methylases; Epigenesis, Genetic; Gene Expression Regulation, Neoplastic; Gene Silencing; Histone Deacetylases; Histones; Humans; Hydroxamic Acids; Kidney Neoplasms; MicroRNAs; Promoter Regions, Genetic; RNA; Vorinostat | 2013 |
Combined treatment with low concentrations of decitabine and SAHA causes cell death in leukemic cell lines but not in normal peripheral blood lymphocytes.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Azacitidine; Cells, Cultured; Decitabine; Dose-Response Relationship, Drug; Humans; Hydroxamic Acids; Leukemia; Lymphocytes; Vorinostat | 2013 |
Epigenetic silencing of CHD5, a novel tumor-suppressor gene, occurs in early colorectal cancer stages.
Topics: Adenoma; Azacitidine; Black or African American; Cell Line, Tumor; Cell Movement; Cell Proliferation; Colorectal Neoplasms; Decitabine; DNA Helicases; DNA Methylation; Epigenesis, Genetic; Gene Expression Regulation, Neoplastic; Gene Silencing; Genes, Tumor Suppressor; Histone Deacetylase Inhibitors; Histones; Humans; Hydroxamic Acids; Nerve Tissue Proteins; Promoter Regions, Genetic; Vorinostat | 2014 |
Learning induced epigenetic modifications in the ventral striatum are necessary for long-term memory.
Topics: Analysis of Variance; Animals; Avoidance Learning; Azacitidine; Corpus Striatum; Decitabine; DNA Methylation; Dose-Response Relationship, Drug; Epigenesis, Genetic; Histone Deacetylase Inhibitors; Histone Deacetylases; Hydroxamic Acids; Male; Memory; Mice; Reaction Time; Vorinostat | 2014 |
Decitabine and SAHA-induced apoptosis is accompanied by survivin downregulation and potentiated by ATRA in p53-deficient cells.
Topics: Antimetabolites, Antineoplastic; Apoptosis; Azacitidine; Cell Line, Tumor; Decitabine; Down-Regulation; Drug Synergism; G2 Phase Cell Cycle Checkpoints; HL-60 Cells; Humans; Hydroxamic Acids; Inhibitor of Apoptosis Proteins; Lymphocytes; M Phase Cell Cycle Checkpoints; Reactive Oxygen Species; Survivin; Tretinoin; Tumor Suppressor Protein p53; Vorinostat | 2014 |
Analysis of the antiproliferative effects of 3-deazaneoplanocin A in combination with standard anticancer agents in rhabdoid tumor cell lines.
Topics: Adenosine; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Azacitidine; Cell Line, Tumor; Cell Proliferation; Decitabine; Doxorubicin; Enhancer of Zeste Homolog 2 Protein; Epigenesis, Genetic; Etoposide; Gene Expression Regulation, Neoplastic; Humans; Hydroxamic Acids; Molecular Targeted Therapy; Polycomb Repressive Complex 2; Rhabdoid Tumor; Vorinostat | 2015 |
Visualization of positive transcription elongation factor b (P-TEFb) activation in living cells.
Topics: Apoptosis; Azacitidine; Bacterial Proteins; Cell-Free System; Genetic Complementation Test; Glycerol; HEK293 Cells; HeLa Cells; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Luminescent Proteins; Microscopy, Fluorescence; Plasmids; Positive Transcriptional Elongation Factor B; Protein Kinase C; Protein Structure, Tertiary; Ribonucleoproteins; Ribonucleoproteins, Small Nuclear; RNA-Binding Proteins; Time Factors; Transcription, Genetic; Vorinostat | 2015 |
Direct but no transgenerational effects of decitabine and vorinostat on male fertility.
Topics: Animals; Azacitidine; Decitabine; DNA Methylation; Endocrine Disruptors; Epididymis; Fertility; Flow Cytometry; Hydroxamic Acids; Male; Mice; Mice, Inbred C57BL; Spermatozoa; Testis; Vorinostat | 2015 |
The epigenetic agents suberoylanilide hydroxamic acid and 5‑AZA‑2' deoxycytidine decrease cell proliferation, induce cell death and delay the growth of MiaPaCa2 pancreatic cancer cells in vivo.
Topics: Animals; Antineoplastic Agents; Azacitidine; Blotting, Western; Cell Death; Cell Line, Tumor; Cell Proliferation; Decitabine; Disease Models, Animal; Female; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Mice; Mice, Inbred BALB C; Mice, Nude; Pancreatic Neoplasms; Vorinostat | 2015 |
Epigenetic modification and preliminary investigation of the mechanism of the immune evasion of HL-60 cells.
Topics: Antimetabolites, Antineoplastic; Azacitidine; B7-1 Antigen; CD40 Antigens; CpG Islands; Decitabine; DNA Methylation; Dose-Response Relationship, Drug; Epigenesis, Genetic; HL-60 Cells; Humans; Hydroxamic Acids; Interferon-gamma; Nuclear Proteins; Promoter Regions, Genetic; Sequence Analysis, DNA; Trans-Activators; Tumor Escape; Vorinostat | 2015 |
Selective inhibition of esophageal cancer cells by combination of HDAC inhibitors and Azacytidine.
Topics: Acetylation; Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Azacitidine; Benzamides; Carcinoma, Squamous Cell; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Movement; Cell Survival; Decitabine; Depsipeptides; DNA (Cytosine-5-)-Methyltransferase 1; DNA (Cytosine-5-)-Methyltransferases; DNA Damage; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Histone Deacetylase Inhibitors; Histones; Humans; Hydroxamic Acids; Pyridines; Transcriptome; Vorinostat | 2015 |
Pax5 Re-expression in H460 Cells Treated with the Combination of Demethylating Agent and Histone Deacetylase Inhibitor is Associated with the Enhancement of P53 Binding to Pax5 Promoter Region.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Gene Expression Regulation, Neoplastic; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Lung Neoplasms; PAX5 Transcription Factor; Promoter Regions, Genetic; Tumor Suppressor Protein p53; Vorinostat | 2017 |
Combined Treatment of ATRA with Epigenetic Drugs Increases Aggressiveness of Glioma Xenografts.
Topics: Animals; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Brain Neoplasms; Cell Line, Tumor; Epigenomics; Female; Glioma; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Mice, Inbred NOD; Mice, SCID; Tretinoin; Tumor Burden; Vorinostat; Xenograft Model Antitumor Assays | 2016 |
Double epigenetic modulation of high-dose chemotherapy with azacitidine and vorinostat for patients with refractory or poor-risk relapsed lymphoma.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Busulfan; Child; Deoxycytidine; Drug Resistance, Neoplasm; Epigenesis, Genetic; Female; Follow-Up Studies; Gemcitabine; Humans; Hydroxamic Acids; Lymphoma; Male; Melphalan; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Prognosis; Survival Rate; Vorinostat; Young Adult | 2016 |
Enhanced inhibition of clonogenic survival of human medulloblastoma cells by multimodal treatment with ionizing irradiation, epigenetic modifiers, and differentiation-inducing drugs.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Cell Differentiation; Cell Line, Tumor; Cell Proliferation; Cell Survival; Cerebellar Neoplasms; Combined Modality Therapy; Decitabine; Dideoxynucleosides; Epigenesis, Genetic; Humans; Hydroxamic Acids; Medulloblastoma; Mice; Neurogenesis; Radiation-Sensitizing Agents; Resveratrol; Stilbenes; Treatment Outcome; Tretinoin; Valproic Acid; Vorinostat; Xenograft Model Antitumor Assays | 2016 |
Concerted changes in transcriptional regulation of genes involved in DNA methylation, demethylation, and folate-mediated one-carbon metabolism pathways in the NCI-60 cancer cell line panel in response to cancer drug treatment.
Topics: Antineoplastic Agents; Azacitidine; Cell Line, Tumor; Cisplatin; Computational Biology; DNA Methylation; Doxorubicin; Epigenesis, Genetic; Folic Acid; Gene Expression Regulation, Neoplastic; Gene Regulatory Networks; Humans; Hydroxamic Acids; Paclitaxel; Vorinostat | 2016 |
Suberanilohydroxamic acid (vorinostat) synergistically enhances the cytotoxicity of doxorubicin and cisplatin in osteosarcoma cell lines.
Topics: Adenosine; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Bone Neoplasms; Cell Growth Processes; Cell Line, Tumor; Cisplatin; Doxorubicin; Drug Synergism; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Osteosarcoma; Vorinostat | 2016 |
Sensitization of retinoids and corticoids to epigenetic drugs in MYC-activated lung cancers by antitumor reprogramming.
Topics: Animals; Antimetabolites, Antineoplastic; Antineoplastic Agents; Apoptosis; Azacitidine; Biomarkers, Tumor; Cell Proliferation; DNA Helicases; DNA Methylation; Drug Resistance, Neoplasm; Glucocorticoids; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Lung Neoplasms; Male; Mice; Mice, Nude; Mutation; Nuclear Proteins; Proto-Oncogene Proteins c-myc; Transcription Factors; Tretinoin; Tumor Cells, Cultured; Vorinostat; Xenograft Model Antitumor Assays | 2017 |
An Epigenomic Approach to Improving Response to Neoadjuvant Cisplatin Chemotherapy in Bladder Cancer.
Topics: Antineoplastic Agents; Azacitidine; Biomarkers, Tumor; Cell Line, Tumor; Cisplatin; Decitabine; Doxorubicin; Drug Resistance, Neoplasm; Epigenomics; Etoposide; Homeodomain Proteins; Humans; Hydroxamic Acids; Methylation; Neoadjuvant Therapy; Promoter Regions, Genetic; Urinary Bladder Neoplasms; Vinblastine; Vorinostat | 2016 |
An Insight into the Secondary Metabolism of Muscodor yucatanensis: Small-Molecule Epigenetic Modifiers Induce Expression of Secondary Metabolism-Related Genes and Production of New Metabolites in the Endophyte.
Topics: Amino Acid Sequence; Azacitidine; Brefeldin A; DNA, Fungal; Endophytes; Epigenomics; Ergosterol; Gene Expression Regulation, Fungal; Genes, Fungal; Hydroxamic Acids; Peptide Synthases; Phenotype; Phylogeny; Polyketide Synthases; Polymerase Chain Reaction; Protein Conformation; Secondary Metabolism; Sequence Alignment; Volatile Organic Compounds; Vorinostat; Xylariales | 2017 |
Mechanistic insights into epigenetic modulation of ethanol consumption.
Topics: Action Potentials; Alcohol Drinking; Animals; Azacitidine; Behavior, Animal; Binge Drinking; Decitabine; DNA Modification Methylases; Dopaminergic Neurons; Enzyme Inhibitors; Epigenesis, Genetic; Ethanol; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Male; Mice, Inbred C57BL; Reward; Time Factors; Transcriptome; Ventral Tegmental Area; Vorinostat | 2017 |
Improving Outcomes in High-Risk Myelodysplasia: Festina Lente.
Topics: Azacitidine; Humans; Lenalidomide; Leukemia, Myelomonocytic, Chronic; Myelodysplastic Syndromes; United States; Vorinostat | 2017 |
Epigenetic Combination Therapy for Children With Secondary Myelodysplastic Syndrome (MDS)/Acute Myeloid Leukemia (AML) and Concurrent Solid Tumor Relapse.
Topics: Adolescent; Antineoplastic Agents; Azacitidine; Decitabine; Drug Therapy, Combination; Epigenesis, Genetic; Female; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes; Neoplasms, Second Primary; Palliative Care; Quality of Life; Vorinostat | 2017 |
Synthesis of secondary metabolites by Cladosporium resinae (NRL-6437) under different growth media and chemical inducers and their pharmaceutical activity.
Topics: Acetates; Animals; Anti-Bacterial Agents; Antifungal Agents; Araceae; Artemia; Azacitidine; Bacteria; Chemical Fractionation; Cladosporium; Dose-Response Relationship, Drug; Epigenesis, Genetic; Fungi; Gene Expression Regulation, Fungal; Hexanes; Histone Deacetylase Inhibitors; Industrial Microbiology; Lethal Dose 50; Solvents; Vorinostat | 2017 |
Synergistic effects of the combination of 5-Aza‑CdR and suberoylanilide hydroxamic acid on the anticancer property of pancreatic cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Cell Cycle; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cell Survival; Cyclin-Dependent Kinase Inhibitor p16; Decitabine; Drug Synergism; Gene Expression Regulation, Neoplastic; Humans; Hydroxamic Acids; Pancreatic Neoplasms; Signal Transduction; Tumor Suppressor Protein p53; Up-Regulation; Vorinostat | 2018 |
Suberanilohydroxamic acid prevents TGF-β1-induced COX-2 repression in human lung fibroblasts post-transcriptionally by TIA-1 downregulation.
Topics: Adenosine; Azacitidine; Cell Line; Cyclooxygenase 1; Cyclooxygenase 2; Decitabine; DNA Methylation; Enhancer of Zeste Homolog 2 Protein; Fibroblasts; Gene Expression Regulation; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Lung; Promoter Regions, Genetic; T-Cell Intracellular Antigen-1; Transforming Growth Factor beta1; Vorinostat | 2018 |
Isolation and enhancement of resveratrol production in Xylaria psidii by exploring the phenomenon of epigenetics: using DNA methyltransferases and histone deacetylase as epigenetic modifiers.
Topics: Azacitidine; DNA; DNA Methylation; DNA Modification Methylases; Epigenesis, Genetic; Epigenomics; Histone Deacetylase Inhibitors; Histone Deacetylases; Hydroxamic Acids; Resveratrol; Vorinostat; Xylariales | 2019 |
The wolf of hypomethylating agent failure: what comes next?
Topics: Animals; Azacitidine; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes; Vorinostat; Wolves | 2019 |
Epigenetic modulation of secondary metabolite profiles in Aspergillus calidoustus and Aspergillus westerdijkiae through histone deacetylase (HDAC) inhibition by vorinostat.
Topics: Aspergillus; Azacitidine; Enzyme Inhibitors; Epigenesis, Genetic; Histone Deacetylase Inhibitors; Multigene Family; Secondary Metabolism; Vorinostat | 2020 |
Global miRNA/proteomic analyses identify miRNAs at 14q32 and 3p21, which contribute to features of chronic iron-exposed fallopian tube epithelial cells.
Topics: Azacitidine; Biomarkers, Tumor; Cell Line, Transformed; Cell Transformation, Neoplastic; Down-Regulation; Epithelial Cells; Fallopian Tubes; Female; Ferric Compounds; Gene Expression Profiling; Genetic Loci; Humans; MDS1 and EVI1 Complex Locus Protein; MicroRNAs; Ovarian Neoplasms; Proteome; Proteomics; Quaternary Ammonium Compounds; Transcriptome; Transfection; Vorinostat | 2021 |
Characterisation of miRNA Expression in Dental Pulp Cells during Epigenetically-Driven Reparative Processes.
Topics: Azacitidine; Decitabine; Dental Pulp; Histone Deacetylase Inhibitors; Hydroxamic Acids; MicroRNAs; Vorinostat | 2023 |